
Sign up to save your podcasts
Or
GLOBAL GENES WAS GREAT
Panel was impressive, will be sharing when recording is live, one point was small molecules…
3 weeks!
8 weeks!
Talked about this in #s10e27 https://youtu.be/r3bS9YepQ4s
We are investing in small molecule repurposing as fast as we can. Four lines…
Cannonball 2.0 is on! Checkout UFDtech on 21 October 2022!
LINK#UFDtech #CannonballForTheCure #RareBase
NOSPHARMA
Talked about Bowie in #s10e69 https://www.youtube.com/watch?v=xl_r4hoDlf8
Nospharma leverages unique biological causes of brain disorders within the context of what is already known, to deliver effective treatments. By placing biology-first, we've created new drugs and repurposed on-the-market drugs to improve treatment success. We aim to deliver the most effective therapeutics for some of the most severe brain disorders, as quickly as possible.
Two of the most important players in the Rare Epilepsy Ecosystem are partnering and it’s great news for SYNGAP1 and SRF.
Satterstrom paper associates SYNGAP1 with Autism strongly
AUTISM BRAIN NETWORK
Webinar: https://www.syngapresearchfund.org/webinars/an-introduction-to-autism-brainnet Site: https://www.autismbrainnet.org/Â
etc.
This is a podcast: subscribe to and rate this 10 minute #podcast #SYNGAP10 here https://www.syngapresearchfund.org/syngap10-podcastÂ
Apple podcasts: https://syngap.fund/10a
Â
Episode 75 of Syngap10 - September 18, 2022Â
Â
#Syngap #SYNGAP1 #epilepsy #autism #intellectualdisability #id #anxiety #raredisease #epilepsyawareness #autismawareness #rarediseaseresearch #SynGAPResearchFund #CareAboutRare #PatientAdvocacy #GCchat #Neurology
5
8383 ratings
GLOBAL GENES WAS GREAT
Panel was impressive, will be sharing when recording is live, one point was small molecules…
3 weeks!
8 weeks!
Talked about this in #s10e27 https://youtu.be/r3bS9YepQ4s
We are investing in small molecule repurposing as fast as we can. Four lines…
Cannonball 2.0 is on! Checkout UFDtech on 21 October 2022!
LINK#UFDtech #CannonballForTheCure #RareBase
NOSPHARMA
Talked about Bowie in #s10e69 https://www.youtube.com/watch?v=xl_r4hoDlf8
Nospharma leverages unique biological causes of brain disorders within the context of what is already known, to deliver effective treatments. By placing biology-first, we've created new drugs and repurposed on-the-market drugs to improve treatment success. We aim to deliver the most effective therapeutics for some of the most severe brain disorders, as quickly as possible.
Two of the most important players in the Rare Epilepsy Ecosystem are partnering and it’s great news for SYNGAP1 and SRF.
Satterstrom paper associates SYNGAP1 with Autism strongly
AUTISM BRAIN NETWORK
Webinar: https://www.syngapresearchfund.org/webinars/an-introduction-to-autism-brainnet Site: https://www.autismbrainnet.org/Â
etc.
This is a podcast: subscribe to and rate this 10 minute #podcast #SYNGAP10 here https://www.syngapresearchfund.org/syngap10-podcastÂ
Apple podcasts: https://syngap.fund/10a
Â
Episode 75 of Syngap10 - September 18, 2022Â
Â
#Syngap #SYNGAP1 #epilepsy #autism #intellectualdisability #id #anxiety #raredisease #epilepsyawareness #autismawareness #rarediseaseresearch #SynGAPResearchFund #CareAboutRare #PatientAdvocacy #GCchat #Neurology
223,304 Listeners
28,392 Listeners
276 Listeners
41,523 Listeners
20 Listeners
18 Listeners
14,078 Listeners